Helical has raised $10M to build the application layer that makes bio foundation models reproducible in pharma R&D. It’s already in production with Pfizer.

TNW is a technology media company that covers the latest trends, news, and insights in the tech industry. With a focus on innovation, entrepreneurship, and digital culture, TNW offers resources for developers, startups, and tech enthusiasts. Developers can learn about emerging technologies, industry trends, and best practices through TNW's articles, podcasts, and events.

The Next Web

Helical, a London-based pharma AI startup, has raised $10M in a seed round led by redalpine to build the application layer that makes biological foundation models usable in pharmaceutical R&D. The platform includes a Virtual Lab for biologists and a Model Factory for ML engineers, both sharing data and models for reproducible, auditable results. Already in production with multiple top-20 global pharma companies including Pfizer, Helical claims to have compressed drug discovery timelines from years to weeks. Notable angel investors include the CEOs of Cohere and HuggingFace.

Helical closes $10M seed to turn bio foundation models into systems